Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Superbug surveillance: 14,000 patients swabbed to map resistance

NCT ID NCT04937361

Knowledge-focused Sponsor: University of Luebeck Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study monitored over 14,000 hospital patients for multidrug-resistant organisms (MDROs) by taking rectal swabs and tracking bloodstream infections. Researchers analyzed the bacteria's genetics and how they resist antibiotics, aiming to understand how resistance emerges and spreads. The study also looked at how COVID-19 infection control measures affected hospital-acquired infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help hospitals better track and control the spread of drug-resistant bacteria, improving infection prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It does not test any new drug or intervention, so it cannot directly lead to a cure or therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14,607 people

The number who actually took part.

Started

Jun 2021

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For the prevalence, adult patients admitted to the hosptial within the last 3 days. For BSI surveillance, adult inpatients with at least one blood culture positive for any of the target organisms: Staphylococcus aureus, Enterococcus spp., Escherichia coli, Enterobacter spp., Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * at least 18 years old * informed consent * inpatient Exclusion Criteria: * less than 18 years old * Not capable of giving informed consent * outpatient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDRO are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MDRO

Contacts and locations

Locations

  • Klinik für Infektiologie und Mikrobiologie

    Lübeck, Germany